Published in MAbs on January 04, 2010
Bispecific small molecule-antibody conjugate targeting prostate cancer. Proc Natl Acad Sci U S A (2013) 1.52
Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm (2014) 0.79
Next generation of antibody therapy for cancer. Chin J Cancer (2011) 0.76
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res (2006) 13.98
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A (2006) 3.54
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem (2006) 2.58
Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol (2008) 2.52
Drug delivery and transport to solid tumors. Pharm Res (2003) 2.05
Extravascular diffusion in normal and neoplastic tissues. Cancer Res (1984) 2.04
Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res (2003) 1.87
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med (1990) 1.85
Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol (2008) 1.74
Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer (2007) 1.68
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res (2007) 1.67
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res (2007) 1.48
18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med (2008) 1.29
Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther (2006) 1.28
Antibody-based therapy for solid tumors. Cancer J (2008) 1.24
Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today (2007) 1.22
DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel (2007) 1.13
The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother (1991) 1.02
Comparison of recombinant derivatives of chimeric TNT-3 antibody for the radioimaging of solid tumors. Hybrid Hybridomics (2003) 0.90
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques (2005) 0.88
An antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performance. Int J Radiat Oncol Biol Phys (2002) 0.88
Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass. Eur J Nucl Med (1993) 0.79
Cancers exhibit a mutator phenotype: clinical implications. Cancer Res (2008) 2.36
Genetic instability is not a requirement for tumor development. Cancer Res (2008) 1.68
SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK). Cancer Biol Ther (2010) 1.49
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2011) 1.36
Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res (2007) 1.27
Antibody-based therapy for solid tumors. Cancer J (2008) 1.24
Alpha-v integrins as therapeutic targets in oncology. Cancer Invest (2007) 1.22
Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res (2013) 1.21
In vivo site-directed radiotracers: a mini-review. Nucl Med Biol (2008) 1.19
Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ). Mol Imaging Biol (2004) 1.00
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer (2012) 0.95
Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res (2009) 0.94
Molecular imaging of death receptor 5 occupancy and saturation kinetics in vivo by humanized monoclonal antibody CS-1008. Clin Cancer Res (2013) 0.88
Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques (2005) 0.88
Optimal cost-effective designs of Phase II proof of concept trials and associated go-no go decisions. J Biopharm Stat (2009) 0.84
Self-assembled, deterministic carbon nanotube wiring networks. Angew Chem Int Ed Engl (2002) 0.81
A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer. Lung Cancer (2013) 0.80
The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity. Bioorg Med Chem Lett (2010) 0.78
Reply: Is There Any Genetic Instability in Human Cancer? DNA Repair (Amst) (2010) 0.76
Maximizing return on socioeconomic investment in phase II proof-of-concept trials. Clin Cancer Res (2014) 0.75